The purpose of the Biostatistics Core is to support the dinical and laboratory-based projects of this program project so that research studies are efficiently designed, conducted, monitored, and analyzed. To ensure that scientifically valid conclusions can be drawn from these experiments, this includes statistical modeling, hypothesis formalization, design of laboratory experiments, clinical trial design, and data analysis. These activities in tum may require development of innovative statistical methods as needed to address new statistical problems as they arise, and accompanying development of appropriate new computer programs to implement these methods. All of these activities are carried out in collaboration with the laboratory and clinical investigators. The specific objectives are:
Aim 1 To provide biostatistical consultation and collaboration in the planning, conduct, analysis and reporting of clinical trials in CML, including phase I trials to determine safe dose combinations, phase II trials to assess therapeutic efficacy, randomized trials to compare competing treatments, and hybrid trials having multiple goals. Trials involving biologic agents or specific types of lymphocytes or stem cells are especially relevant. These statistical designs accommodate multiple patient outcomes, including toxicity, regimen-related death, complete remission (CR), graft-versus-host disease (GVHD) in allogeneic transplantation (allotx) trials, and times to disease remission, progression, onset of CML accelerated phase, blast crisis, and death. Many of the designs accommodate patient heterogeneity by stratification or regression models.that account for patient prognostic characteristics, to help develop individualized treatments when treat-prognosis interactions exist.
Aim 2. To consult and collaborate with researchers evaluating the cellular and molecular basis of response.
Aim 3. T0 develop novel statistical methods for clinical trial design and data analysis as required to address special goals and needs of the projects.
Aim 4. To evaluate prognostic significance of innovative treatments and possible synergistic effects with specific biological and molecular markers. This includes regression, data analysis, and hypothesis formulation.

Public Health Relevance

The statistical methods applied in this program project will ensure that the laboratory experiments and clinical trials are designed reliably and efficiently in order to conserve resources and ensure that valid inferences may be drawn from the resulting data. This also will ensure that the clinical trials meet high ethical standards. In tum, this will enhance the likelihood of achieving the ultimate goal of this research, which is to improve the diagnosis and treatment of CML

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W et al. (2018) Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237
Sasaki, Koji; Kantarjian, Hagop; O'Brien, Susan et al. (2018) Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124:1160-1168
Gambacorti-Passerini, Carlo; Cortes, Jorge E; Lipton, Jeff H et al. (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298-1307
Boddu, Prajwal; Shah, Abdul Rashid; Borthakur, Gautam et al. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312-1322
Kornblau, Steven M; Ruvolo, Peter P; Wang, Rui-Yu et al. (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810-821
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Boddu, Prajwal; Benton, Christopher B; Wang, Wei et al. (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32:96-105

Showing the most recent 10 out of 375 publications